Your search returned 18 results.

Results
	1.	Late side-effects of breast cancer radiotherapy: second cancer incidence and non-breast-cancer mortality among 40,000 women in 75 trials MedStar authors: Swain, Sandra M Year: 2015 Citation: Unpublished 2015 Dec 8 Institution: Washington Cancer Institute Form of publication: Conference All authors: Swain S Local accession number: 2015_3 Add to cart (remove)
	2.	Late side-effects of breast cancer radiotherapy: second cancer incidence and non-breast-cancer mortality among 40,000 women in 75 trials MedStar authors: Swain, Sandra M Year: 2015 Citation: Unpublished 2015 Dec 8 Institution: Washington Cancer Institute Form of publication: Conference All authors: Swain S Local accession number: 2015_3 Add to cart (remove)
	3.	Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer MedStar authors: Swain, Sandra M Year: 2016 Citation: Unpublished 2016/12/05 Form of publication: Poster Presentation All authors: Swain SM Local accession number: 2016_350 Add to cart (remove)
	4.	ESR1 mutations, ESR1 fusions and co-occurring alterations assessed in breast cancer tumors MedStar authors: Swain, Sandra M Year: 2016 Citation: Unpublished 2016/12/05 Form of publication: Poster Presentation All authors: Swain SM Local accession number: 2016_349 Add to cart (remove)
	5.	Late side-effects of breast cancer radiotherapy: second cancer incidence and non-breast-cancer mortality among 40,000 women in 75 trials MedStar authors: Swain, Sandra M Year: 2015 Citation: Unpublished 2015 Dec 8 Institution: Washington Cancer Institute Form of publication: Conference All authors: Swain S Local accession number: 2015_3 Add to cart (remove)
	6.	Late side-effects of breast cancer radiotherapy: second cancer incidence and non-breast-cancer mortality among 40,000 women in 75 trials MedStar authors: Swain, Sandra M Year: 2015 Citation: Unpublished 2015 Dec 8 Institution: Washington Cancer Institute Form of publication: Conference All authors: Swain S Local accession number: 2015_3 Add to cart (remove)
	7.	Prognostic associations of tumor-infiltrating lymphocytes (TIL) in metastatic HER2-positive breast cancer (BC) treated with trastuzumab and pertuzumab: a secondary analysis of the CLEOPATRA study MedStar authors: Swain, Sandra M Year: 2016 Institution: Washington Cancer Institute Form of publication: Conference All authors: Swain SM Local accession number: 2016_346 Add to cart (remove)
	8.	Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab MedStar authors: Swain, Sandra M Year: 2015 Citation: Unpublished 2015 Dec 8 Form of publication: Poster Presentation All authors: Swain S Local accession number: 2015_344 Add to cart (remove)
	9.	Increasing participation in research - Breast cancer MedStar authors: Swain, Sandra M Year: 2015 Citation: Unpublished 2015 Dec 8 Form of publication: Poster Presentation All authors: Swain S Local accession number: 2015_347 Add to cart (remove)
	10.	Baseline (BL) characteristics, treatment (tx) patterns, and outcomes in patients with hormone receptor (HR)+ vs. HR-HER2+ disease from the SystHERs registry MedStar authors: Swain, Sandra M Year: 2016 Citation: Unpublished 2016/12/05 Form of publication: Poster Presentation All authors: Swain SM Local accession number: 2016_351 Add to cart (remove)
	11.	Effect of docetaxel duration on clinical outcomes: results from the phase III trial CLEOPATRA MedStar authors: Swain, Sandra M Year: 2015 Citation: Unpublished 2015 Dec 8 Form of publication: Poster Presentation All authors: Swain S Local accession number: 2015_345 Add to cart (remove)
	12.	Consensus and disagreement between experts and community practitioners asked to make therapeutic recommendations for early breast cancer (EBC) MedStar authors: Swain, Sandra M Year: 2015 Citation: Unpublished 2015 Dec 8 Form of publication: Poster Presentation All authors: Swain S Local accession number: 2015_348 Add to cart (remove)
	13.	Central nervous system metastases at diagnosis in patients with HER2+ MBC: Baseline characteristics, HER2-targeted treatments and clinical outcomes from the SystHERs registry MedStar authors: Swain, Sandra M Year: 2015 Citation: Unpublished 2015 Dec 8 Form of publication: Poster Presentation All authors: Swain S Local accession number: 2015_349 Add to cart (remove)
	14.	Increasing participation in research - breast cancer (Inspire-BrC) MedStar authors: Swain, Sandra M Year: 2016 Citation: Unpublished 2016/12/05 Form of publication: Poster Presentation All authors: Swain SM Local accession number: 2016_348 Add to cart (remove)
	15.	A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG oncology/NSABP B-52 MedStar authors: Swain, Sandra M Year: 2016 Citation: Unpublished 2016/12/05 Form of publication: Poster Presentation All authors: Swain SM Local accession number: 2016_347 Add to cart (remove)
	16.	A randomized, double-blinded, placebo-controlled clinical trial to evaluate extended adjuvant endocrine therapy (5 years of letrozole) in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant endocrine therapy: initial results of NRG oncology/NSABP B-42 MedStar authors: Swain, Sandra M Year: 2016 Institution: Washington Cancer Institute Form of publication: Conference All authors: Swain SM Local accession number: 2016_345 Add to cart (remove)
	17.	Oral presentation skills Career Development Forum: A Networking Session for Young Investigators MedStar authors: Swain, Sandra M Year: 2016 Institution: Washington Cancer Institute Form of publication: Conference All authors: Swain SM Local accession number: 2016_344 Add to cart (remove)
	18.	Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: the OXEL study. MedStar authors: Dilawari, Asma Gallagher, Christopher Khoury, Katia Lynce, Filipa Swain, Sandra M Year: 2018 Department: MedStar Georgetown University Hospital Residents Form of publication: Conference All authors: Khoury K, Isaacs C, Gatti-Mays M, Donahue R, Schlom J, Wang H, Gallagher C, Graham D, Warren R, Dilawari A, Swain S, Pohlmann P, Lynce F. Local accession number: C2019_426 Add to cart (remove)

Powered by Koha